Atosiban

GENITO URINARY SYSTEM AND SEX HORMONES

Key facts

Atosiban is a drug catalogued in DrugCentral. It was first approved by the EMA in 2000. DrugCentral lists 5 molecular targets, including AVPR1A, OXTR and Oxtr. Recorded indications include Prevention of Premature Labor.

• Molecular targets: AVPR1A, OXTR, Oxtr and AVPR1B (5 listed in DrugCentral).
• Indications: Prevention of Premature Labor.
• ATC code: G02CX01 (Other gynecologicals).
• Molecular formula: C43H67N11O12S2; molecular weight 994.19 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Prevention of Premature Labor

Mechanism & targets

Molecular targets (5)

Target	Gene	Action	Activity
Vasopressin V1a receptor	AVPR1A	unknown	Ki 9.82
Oxytocin receptor	OXTR	antagonist	Ki 7.96
Oxytocin receptor	Oxtr	unknown	Ki 7.40
Vasopressin V1b receptor	AVPR1B	unknown	Ki 7.36
Vasopressin V2 receptor	AVPR2	unknown	Ki 6.48

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2000-01-20	EMA	—	Ferring Pharmaceuticals A/S

ATC classification

ATC code	Therapeutic hierarchy
G02CX01	GENITO URINARY SYSTEM AND SEX HORMONES › OTHER GYNECOLOGICALS › OTHER GYNECOLOGICALS › Other gynecologicals

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Premature baby	1204.7
Premature delivery	1008.9
Normal labour	898.6
Maternal exposure during pregnancy	801.3
Delivery	778.8
Foetal exposure during pregnancy	407.5
Product use in unapproved indication	275.9
Low birth weight baby	232.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Atosiban is on its molecule page.

• Molecular formula: C₄₃H₆₇N₁₁O₁₂S₂
• Molecular weight: 994.19 g/mol
• CAS number: 90779-69-4
• InChIKey: VWXRQYYUEIYXCZ-OBIMUBPZSA-N
• PubChem CID: 5311010

CCOC1=CC=C(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Atosiban used for?

DrugCentral lists the following indications for Atosiban: Prevention of Premature Labor.

How does Atosiban work?

Its molecular targets in DrugCentral include AVPR1A, OXTR (antagonist), Oxtr and AVPR1B.

When was Atosiban first approved?

Atosiban was first approved by the EMA in 2000.

What is the chemical formula of Atosiban?

Atosiban has the molecular formula C43H67N11O12S2 and a molecular weight of 994.19 g/mol.

Sources

• DrugCentral drug card 3008 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL382301 — compound record and bioactivity
• PubChem CID 5311010 — chemical identifiers
• DrugBank DB09059 — drug record
• FDA UNII 081D12SI0Z — substance identity
• UniProt P37288 (AVPR1A) — target protein
• UniProt P30559 (OXTR) — target protein
• UniProt P47901 (AVPR1B) — target protein
• UniProt P30518 (AVPR2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.